Shenwei Pharmaceutical Industry(02877) the interim results for 2020 were released, during which the company achieved a turnover of RMB 1.19 billion, down 13.0% from the same period last year, and the profit for the period attributable to shareholders was RMB 254 million, down 11.8% from the same period last year. Earnings per share are RMB 33 cents, paying an interim dividend of RMB 11 cents per share.

The announcement said that due to the impact of public health events, the number of medical visits decreased significantly. According to the data released by the National Health Commission, the total number of patients in medical and health institutions across the country from January to June 2020 decreased by 21.6% compared with the same period last year, while the group's sales in the first six months of 2020 decreased by 13.0% compared with the same period last year. Net profit was 254 million yuan, down 11.8% from the same period last year, mainly due to a decline in sales. Net profit margin rose to 21.3 per cent from 21.0 per cent in the same period last year, while earnings per share fell only 8.3 per cent to 33 cents from last year. Although the performance failed to meet the original growth target, it was better than the contraction in the overall usage of medical services.

Although the overall sales of the group's soft capsule products decreased in the first quarter of this year, they resumed growth in the second quarter. Among them, the sales of key products such as Wufuxinnaoqing soft capsule, Huoxiangzhengqi soft capsule and Qingkailing soft capsule increased by 15.3% 1.8% and 50.8% respectively in the first half of the year. Overall sales of soft capsule products increased by 5.4% in the first six months of 2020 compared with the same period last year.